Edition:
United Kingdom

Boston Scientific Corp (BSX.N)

BSX.N on New York Stock Exchange

37.29USD
20 May 2019
Change (% chg)

$-0.03 (-0.08%)
Prev Close
$37.32
Open
$37.15
Day's High
$37.38
Day's Low
$36.81
Volume
1,151,162
Avg. Vol
1,832,344
52-wk High
$41.00
52-wk Low
$29.96

Select another date:

Wed, Apr 24 2019

Boston Scientific trims 2019 sales growth forecast on weak first quarter, shares fall

Boston Scientific Corp on Wednesday posted a rare first-quarter profit and revenue miss and lowered the top end of its 2019 sales growth forecast as the medical device maker faces regulatory scrutiny for some of its products.

Boston Scientific sees $25 million hit to 2019 revenue from mesh withdrawal

Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products.

Boston Scientific sees $25 mln hit to 2019 revenue from mesh withdrawal

April 17 Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products.

Edward Lifesciences pays Boston Scientific $180 million to end patent row

Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.

UPDATE 2-Edward Lifesciences pays Boston Scientific $180 mln to end patent row

Jan 15 Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.

Edward Lifesciences settles patent disputes with Boston Scientific

Jan 15 Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement related to all outstanding patent disputes between the companies, the medical device makers said in a joint statement on Tuesday.

Boston Scientific backs BTG offer with £3.3bn bridge loan

LONDON, Nov 21 (LPC) - US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn (US$4.22bn)bridge loan from Barclays Bank.

Select another date: